Ireland
--:--IST
Priya Life Science Medicines register
Registers› Irish medicines ›Lamisil Once 1% cutaneous solution
Medicines register · Ireland

Lamisil Once 1% cutaneous solution

Authorisation PA22650/009/003 · Karo Pharma AB

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 18 Nov 2026
Licence holder
Karo Pharma AB (all products →)
Active substance
Terbinafine
Clinical trials
4 clinical trials →
Dosage form
Cutaneous solution
Route of administration
Cutaneous use
ATC codes
D01AE, D01AE15
First authorised
29/09/2006
Prescription status
Product not subject to medical prescription
Supply
Supply through pharmacies only
Legal basis
Full application (Article 8(3) of Directive No 2001/83/EC)

Terbinafine: supply and approvals

11 authorised products on the HPRA list contain Terbinafine. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 17 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 17 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 17 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 20 years (since 29 September 2006). The HPRA list marks it as marketed in Ireland.

Other medicines with Terbinafine in Ireland

5 other products on the HPRA list contain Terbinafine, from 5 licence holders; 4 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Fungasil 250 mg tabletsClonmel Healthcare LtdNational authorisation (PA)Marketed
Nailderm 250 mg tabletsViatris LimitedNational authorisation (PA)Marketed
Terbasil 250 mg tabletsAccord Healthcare Ireland Ltd.National authorisation (PA)Marketed
Terbinafine Rowa 250 mg tabletsRowa Pharmaceuticals LimitedNational authorisation (PA)Marketed
Lamisil 250 mg tabletsPCO Manufacturing Ltd.Parallel import (PPA)Not stated

Other substances in ATC group D01AE

The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 8 other active substances share the group D01AE with this product:

Amorolfine (4) · Zinc undecylenate (3) · Terbinafine hydrochloride (3) · Calcium undecylenate (2) · Undecylenic acid (2) · Ciclopirox (1) · Salicylic acid (1) · Benzoic acid (1)

Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.

The licence holder

Karo Pharma AB holds 14 products on the HPRA list, with 16 different active substances; 11 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 18 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.